RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BUONADONNA A
Collezione AO Cuneo

Items : 7

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. in British journal of cancer / Br J Cancer. 2021 Jan;124(1):183-190. doi: 10.1038/s41416-020-01089-9. Epub 2020 Oct 7.

2021
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Falcone A; Latiano TP; Rapisardi S; Ritorto G; Masi G; Buonadonna A; Pietrantonio F; Moretto R; Zaniboni A; Caponnetto S; Ricci V; Germani MM; Lonardi S; Antoniotti C; Bergamo F; Santini D; Ermacora P; Tomasello G; Rossini D;

Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Nov;139:81-89. doi: 10.1016/j.ejca.2020.08.009. Epub 2020 Sep 23.

2020
AO Cuneo

Aprile G; Grande R; Boccaccino A; Tamburini E; Fea E; Bordonaro R; Marmorino F; Buonadonna A; Pietrantonio F; Zaniboni A; Antoniotti C; Caponnetto S; Tomasello G; Cupini S; Santini D; Bergamo F; Lonardi S; Zucchelli G; Moretto R; Rossini D; Falcone A; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C; Marmorino F; Rossini D; et alii...

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.

2018
AO Cuneo
AOU Città della Salute di Torino

Falcone A; Fontanini G; Boni L; Sensi E; Zagonel V; Masi G; Allegrini G; Granetto C; Buonadonna A; Marmorino F; Tonini G; Zaniboni A; Loupakis F; Ronzoni M; Racca P; Moretto R; Cortesi E; Tomasello G; Lonardi S; Bergamo F; Antoniotti C; Cremolini C; Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; et alii...

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

2018
AO Cuneo
AOU Città della Salute di Torino

Danesi R; Falcone A; Boni L; Zagonel V; Di Donato S; Buonadonna A; Allegrini G; Ricci V; Racca P; Ronzoni M; Tomasello G; Zaniboni A; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Antoniotti C; Lonardi S; Del Re M; Cremolini C;

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

2016
AO Cuneo
AOU Città della Salute di Torino

Bustreo S; Ronzoni M; Buonadonna A; Bergamo F; Tomasello G; Tonini G; Allegrini G; Vitello S; Rossini D; Moretto R; Chiara S; Mancini ML; Granetto C; Lonardi S; Masi G; Loupakis F; Cremolini C; Barbara C; Boni L; Falcone A;